PARP Inhibition in Prostate Cancer: Current Status, Resistance Mechanisms, and Clinical Challenges
Poly(ADP-ribose) polymerase inhibitors (PARPi) have reshaped therapy for advanced prostate cancer, yet durable benefit remains concentrated in BRCA1/2-altered tumors, especially BRCA2, and most responders eventually relapse. Here, we frame PARPi response and resistance through a unifying model in wh...
Сохранить в:
| Главные авторы: | , , , , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
MDPI AG
2026-03-01
|
| Серии: | Cells |
| Предметы: | |
| Online-ссылка: | https://www.mdpi.com/2073-4409/15/7/588 |
| Метки: |
Нет меток, Требуется 1-ая метка записи!
|